Advertisement

Nuclear Medicine and Molecular Imaging

, Volume 53, Issue 6, pp 442–445 | Cite as

68Ga-PSMA: a One-stop Shop in Radioactive Iodine Refractory Thyroid Cancer?

  • Thabo Lengana
  • Ismaheel O. Lawal
  • Kgomotso Mokoala
  • Mariza Vorster
  • Mike M. SathekgeEmail author
Interesting image
  • 21 Downloads

Abstract

We report a case of a 47-year-old female known with metastatic papillary thyroid cancer. Her treatment history included total thyroidectomy and 3 previous radio ablations with a cumulative dose of 950 mCi of 131I. On follow-up, her thyroglobulin levels had demonstrated a rising trend (from 3789.0 to 4240.0 ug/L) despite a 123I whole-body scan demonstrating a reduction in tracer avid lesions. She was suspected of having radio-resistant disease. The patient underwent both 18F-FDG and 68Ga-PSMA PET/CT imaging with both scans demonstrating congruent lesions however with far greater intensity on the 68Ga-PSMA study.

Keywords

68Ga-PSMA 18F-FDG Thyroid cancer Radioactive iodine refractory thyroid 

Notes

Acknowledgments

We would like to thank the staff of the Department of Nuclear Medicine of Steve Biko Academic Hospital for performing the scans.

Funding Information

This study was self-funded by the Department of Nuclear Medicine.

Compliance with Ethical Standards

Conflict of Interest

Thabo Lengana, Ismaheel O. Lawal, Kgomotso Mokoala, Mariza Vorster, and Mike M. Sathekge declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.CrossRefGoogle Scholar
  2. 2.
    Pfister DG, Fagin JA. Refractory thyroid cancer: a paradigm shift in treatment is not far off. J Clin Oncol. 2008;26:4701–4.CrossRefGoogle Scholar
  3. 3.
    Silberstein EB. The problem of the patient with thyroglobulin elevation but negative iodine scintigraphy: the TENIS syndrome. Semin Nucl Med. 2011;41:113–20.CrossRefGoogle Scholar
  4. 4.
    Vural GU, Akkas BE, Ercakmak N, Basu S, Alavi A. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data. Clin Nucl Med. 2012;37:953–9.CrossRefGoogle Scholar
  5. 5.
    Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med. 1996;37:1468–72.PubMedGoogle Scholar
  6. 6.
    Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59:3192–8.PubMedGoogle Scholar
  7. 7.
    Sathekge M, Lengana T, Modiselle M, Vorster M, Zeevaart J, Maes A, et al. (68)Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients. Eur J Nucl Med Mol Imaging. 2017;44:689–94.CrossRefGoogle Scholar
  8. 8.
    Bychkov A, Vutrapongwatana U, Tepmongkol S, Keelawat S. PSMA expression by microvasculature of thyroid tumors - potential implications for PSMA theranostics. Sci Rep. 2017;7:5202.CrossRefGoogle Scholar
  9. 9.
    Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384:319–28.CrossRefGoogle Scholar
  10. 10.
    Paeng JC, Kang KW, Park DJ, Oh SW, Chung JK. Alternative medical treatment for radioiodine-refractory thyroid cancers. Nucl Med Mol Imaging. 2011;45:241–7.CrossRefGoogle Scholar
  11. 11.
    Kim YJ, Kim YI. Therapeutic responses and survival effects of 177Lu-PSMA-617 radioligand therapy in metastatic castrate-resistant prostate cancer: a meta-analysis. Clin Nucl Med. 2018;43:728–34.CrossRefGoogle Scholar

Copyright information

© Korean Society of Nuclear Medicine 2019

Authors and Affiliations

  1. 1.Department of Nuclear MedicineUniversity of Pretoria & Steve Biko Academic HospitalPretoriaSouth Africa

Personalised recommendations